The fixed dose combination dolutegravir sodium with abacavir  sulfate and lamivudine (trade name Triumeq) has been approved since September 2014 for use by adults and adolescents over 12 years who are infected with the human immunodeficiency virus. The Institute for Quality and Efficiency in Health Care (IQWiG), which has already assessed dolutegravir sodium, has now checked in another evaluation dossier whether the drug combination provides an additional benefit compared to the appropriate comparator therapy.

Accordingly, for adults who have not yet been treated their HIV infection, Triumeq has a significant additional benefit. For anti-retroviral treatment-experienced adults and young people with or without pre-treatment, there is no additional benefit compared to the appropriate comparator therapy as the appropriate study data are missing.

For more details, go to: https://www.iqwig.de/de/presse/pressemitteilungen/pressemitteilungen/dolutegravir/abacavir/lamivudin-betrachtlicher-zusatznutzen-fur-therapienaive-erwachsene-mit-hiv.6512.html?&et_cid=4&et_lid=%25208 [German]